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ABSTRACT
The question of when immune reconstitution of cytomegalovirus (CMV)–specific CD8 T cells occurs after
hematopoietic cell transplantation and, more specifically, to which CMV targets this immunity is likely to be
directed remains poorly understood. The dependence of immune reconstitution on CMV reactivation is even
less clear. To better understand these events, 44 CMV-seropositive HLA-A*0201 subjects were followed up at
approximately days 40, 90, 120, 150, 180, and 360 after hematopoietic cell transplantation for CMV immunity
as measured by 2 types of assays: (1) an HLA-A*0201 tetramer-binding assay for both CMV pp65 (pp65) and
immediate-early 1 (IE-1) or (2) intracellular cytokine interferon  responses induced by pp65 or IE-1–derived
peptides. To verify the reliability of IE-1–specific assays relative to the pp65-based assays, a pilot study first
compared the development of IE-1–specific immunity in a subgroup by using multiple HLA-A*0201–restricted
peptides, and then these recipients were followed up for 1 year for immunologic function and for CMV
infection. The IE-1–specific response occurred to each of the 3 HLA-A*0201–restricted peptides studied
(IE-1-256, -297, and -316), and there was no predominant IE peptide response. However, the immunodom-
inant HLA-A*0201–restricted pp65 peptide was recognized significantly more frequently than these IE-1
peptides. When this was compared with the occurrence of CMV infection, the overall immune reactivity, as
measured by the mean or median number of CD8 T cells reactive to either pp65 or IE-1 peptides by
intracellular cytokine or tetramer binding assay, was not significantly different in those with and without CMV
infection. For patients who demonstrated reconstituted immunity to CMV at 1 year, all were reconstituted by
6 months, and the timing of the first observed immune reactivity to either of the pp65 or the IE peptides was
not different in those with and without detectable CMV infection.
© 2005 American Society for Blood and Marrow Transplantation
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sNTRODUCTION
Quantitative assessment of HLA-restricted T-lym-
hocyte recognition of speciﬁc antigens currently ana-
yzes cells by using methods that can enumerate the
inding of recombinant HLA-peptide antigen com-
lexes or the speciﬁc induction of intracellular cyto- t
90ines (ICCs). These methods have been applied to the
nalysis of risk for cytomegalovirus (CMV) complica-
ions after allogeneic hematopoietic cell transplanta-
ion (HCT; see review [1]). Because CMV seems to
ncode more than 200 polypeptides, the immune re-
ponse to CMV is complex and involves multiple pro-
ein targets, and the peptide sequences of the HLA-
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CMV ICC and Tetramer Binding
Bpeciﬁc restriction elements are known for only a few
f the CMV proteins [2]. The most abundant viral
rotein, CMV pp65, is the apparent immunodomi-
ant target of the immune response [3-5], and most
nalyses of the protein-speciﬁc immune response after
CT have focused on CMV pp65.
For CMV pp65, the immune response in HCT
ecipients has been well described [5-9]. In HLA-A*0201–
estricted responses, the pp65-495 (NLVPMVATV)
eptide is known to induce a CMV pp65 protein–
peciﬁc ICC response [4,5,10], and when this peptide
s used to fold recombinant tetrameric major histo-
ompatibility complex molecules, a remarkable num-
er of T cells can often be enumerated [8,11-14]. The
ellular immune response to the CMV pp65 protein is
herefore robust and has been used to characterize the
mmune response to CMV in other HLA contexts,
uch as B7, A1, and B35 [2,8].
By using the binding of CMV pp65–speciﬁc HLA-
eptide complexes to CD8 cells as a measure of CD8
mmunity, it has been reported that levels reaching 10
106 CD8 tet cells per liter are associated with
rotection from CMV disease in HCT recipients [15]
nd that use of ganciclovir for treatment of CMV
nfection is signiﬁcantly less if there are 2  106
D8 tet cells per liter [14]. Few targets of CMV
mmunity have been used in these assessments, and,
ecause of the potential for CMV to selectively escape
rom immune detection, it has been suggested that the
pparent immunodominance of CMV pp65 might
ead to overinterpretation of this protein as an impor-
ant target of protective immunity [16]. Rather, im-
unity to other CMV proteins, especially those made
t immediate early times after infection, might be
rotective. A recent report in CMV-seropositive
eart/lung transplant recipients indicated that immu-
ity to CMV IE-1 and not to CMV pp65 was more
rotective [17].
Less is known about the immune response to
MV IE-1, which is one of the ﬁrst proteins expressed
fter virus reactivation. CMV IE-1 is clearly a target of
-cell immunity after CMV infection, and an early
eport [18], conﬁrmed by others [19], described the
E-1-316 (VLEETSVML)–speciﬁc peptide response
n cells from 6 of 18 HLA-A*0201 subjects by using an
nterferon (IFN)– enzyme-linked immunospot assay.
he IE-1-315 peptide and some of its variants [19,20]
nd IE-1-354 [21] have been reported to trigger cy-
otoxic responses as well. In the primary immune
esponse to CMV infection in infants, it is known that
E-1-316–speciﬁc responses are a major component
f cellular immune reactivity [22]. In addition, we
ave reported that, using transgenic HLA-A*0201
ice immunized with CMV IE-1 DNA, there is CMV
E-1–speciﬁc cytotoxic T-lymphocyte recognition of
everal peptides, including IE-1-297, IE-1-316, and
E-1-256 [23]. p
B&MTThe purpose of this study was to describe the
nset and durability of CMV immune reconstitution
n allogeneic HCT as measured by T-cell immune
ecognition of CMV pp65 and CMV IE-1 and to
ssess the effect of CMV reactivation on quantitative
easures of such cellular immunity. We found that, as
nticipated, the CMV pp65 response was signiﬁcantly
ore robust than the CMV IE-1 responses, but in
ertain recipients, IE-1 responses were higher than
p65-speciﬁc responses. Contrary to conventional
isdom, however, the onset of detectable CMV im-
unity was not dependent on documented CMV vire-
ia or DNA-emia, and there was no statistically sig-
iﬁcant difference between CMV immunity to CMV
p65 and CMV IE-1 in those with and without de-
ectable CMV reactivation. This indicates that occult
MV reactivation is sufﬁcient to induce reconstitu-
ion of immunity in HCT recipients.
ATIENTS AND METHODS
tudy Patients
Allogeneic HCT recipients, including related sibling
onors and recipients of unrelated donor transplants at
isk for CMV infection because of donor and/or recipi-
nt CMV seropositivity, were enrolled at the City of
ope Comprehensive Cancer Center with the approval
f the institutional review board. During 2001 to 2004,
4 recipients were studied. Within this group, a pilot
ubgroup of 11 consecutive HLA-A*0201 subjects and
heir donors, when available, was evaluated for compar-
tive responses to IE-1 peptides and the CMV pp65-495
eptide; this was done with frozen, density-gradient pu-
iﬁed leukocytes. After this, a group of 33 consecutive
LA-A*0201 subjects were analyzed for evidence of
mmunity to IE-1 and CMV pp65 by using fresh whole
lood samples. Donor samples (unrelated donors not
ncluded) were drawn before the administration of gran-
locyte colony-stimulating factor and later at the time of
ell harvest. Recipient blood samples were collected at
ay 40, 90, 120, 150, 180, and 360 after transplantation
or ICC and tetramer-binding assays, and the CMV
eactivation was monitored at day 21 after HCT and
wice weekly until day 100 by using a shell vial assay and
uantitative polymerase chain reaction (PCR). After day
00, CMV was monitored in patients at high risk be-
ause of graft-versus-host disease (GVHD) or immuno-
uppressive medication. Subjects with reactivation of
MV infection as determined by 1 positive shell vial
ample (CMV blood culture [BC]) or 2 consecutive pos-
tive PCR assays (CMV PCR) were treated with pre-
mptive ganciclovir for 6 weeks as previously described
24]. For the purpose of analysis, recipients were placed
nto a CMV group, meaning that they had at least 1
ositive CMV blood shell vial culture or 1 PCR-positive
lasma test, or into a no-CMV group, meaning that
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8hese conditions were not met despite frequent viral
urveillance. All patients underwent90% of the sched-
led viral and immunologic surveillance.
ransplantation Protocol
The HCT protocol was essentially performed as
escribed by Bensinger et al. [25], but the condition-
ng regimen was modiﬁed according to patient age
nd diagnosis. Brieﬂy, the disease-speciﬁc condition-
ng regimens consisted of high-dose chemotherapy
ith or without total body irradiation and were ad-
inistered before transplantation. Most recipients re-
eived peripheral blood stem cells collected after
reatment of the donor with subcutaneous granulocyte
olony-stimulating factor (16 g/kg/d for 4 days). For
ome recipients, marrow was used for transplantation
nd was collected from the donor by standard tech-
iques on the day of infusion.
solation and Preservation of Peripheral Blood
ononuclear Cells
Peripheral blood mononuclear cells from heparin-
reated whole blood were isolated by using Histopaque-
077 (Sigma, St. Louis, MO) density gradients, washed
ith 1 phosphate-buffered saline (PBS), and cryopre-
erved in aliquots of 3 to 5  106 cells per milliliter in
0% fetal bovine serum (HyClone, Logan, UT) and
0% dimethyl sulfoxide (American Type Culture Col-
ection, Manassas, VA). The plasma was collected by
entrifugation, ﬁltered through a 0.45-m Acrodisc
Pall Corp., Ann Arbor, MI), and stored at 20°C
ntil DNA extraction.
uantitative PCR
Quantitative PCR was performed with DNA ex-
racted from 200-L plasma samples by using the
IAamp DNA Blood Minikit (Qiagen, Valencia CA)
nd resuspended in 200 L of elution buffer. A gly-
oprotein B (gB) CMV DNA sequence was ampliﬁed
y using 1 picomole of the forward primer 5=CTG-
CCAGGCCCAAGAC-3=, 1 picomole of the reverse
rimer 5=CGGCCATTTACAACAAACCG3=, and 1
icomole of the probe 5=-FAM-CCCAT-
AAACGCGCGGCA-TAMRA (Applied Biosys-
ems, Foster City, CA) in a 30-L reaction that con-
ained the TaqMan Universal PCR Master Mix
Applied Biosystems) and 10 L of extracted DNA.
he PCR cycles were set according to the manufac-
urer’s protocol: 2 minutes at 50°C and 10 minutes at
5°C, followed by 40 cycles of 15 seconds at 95°C and
minute at 60°C, and the data were collected and
nalyzed on an ABI Prism 7900HT Sequence Detec-
ion System (Applied Biosystems). Serial dilutions
100-106 genome copies [gc]) of the plasmid contain-
ng the ampliﬁed sequence (pDCMVgB) were used
or determination of a standard curve. The sensitivity i
92f the assay was 200 gc/mL of plasma. No PCR
nhibition was detected in samples when the EXO
ene was introduced into the PCR mixture, as de-
cribed by Limaye et al. [26].
eptides
Peptides were synthesized at the City of Hope
eptide-synthesis core facility (IE-1 peptides) or in the
aboratory of D.J.D. (pp65-495 and human immuno-
eﬁciency virus [HIV]–468) by using an ABI 432A
PE Biosystems, Foster City, CA) or a Pioneer (Per-
eptive Biosystems Inc., Framingham, MA) peptide
ynthesizer and standard Fmoc protocols with puriﬁ-
ation to 90% by high-performance liquid chroma-
ography. They were dissolved in 10% dimethyl sul-
oxide/water to a concentration of 5 mmol/L and used
t a ﬁnal concentration of 25 mol/L for T-cell stim-
lation. The following peptides were used: IE-1-256
ILDEERDKV), IE-1-297 (TMYGGISLL), IE-1-
16 (VLEETSVML), pp65-495 (NLVPMVATV; as a
ositive control), and HIV-468 (ILKEPVHGV; as a
egative control).
FN- ICC Detection
For the ﬁrst group of 11 subjects, frozen samples
rom each patient were thawed at 37°C and washed
ith cold RPMI with 10% fetal bovine serum, and
liquots of approximately 1  106 peripheral blood
ymphocytes (PBLs) were stimulated with individual
eptides (pp65-495, IE-1-256, IE-1-297, and IE-1-
16) in separate tubes or an IE-1 peptide mixture in 1
ube, as indicated in the experiment. The positive
timulation control was phytohemagglutinin (Remel,
enexa, KS), and the negative control was HIV pep-
ide. The ICC assay was adapted from Dunn et al. [27]
or frozen cells. After 1 hour of incubation at 37°C in
% carbon dioxide, 1 L (stock 5 mg/mL) of brefeldin
(Sigma), a cytokine secretion inhibitor, was added to
he cells and further incubated overnight.
When fresh blood samples were used for the sec-
nd group of 33 subjects, 200 L of whole blood was
reated as described previously but was incubated at
7°C for only 4 hours. Samples were then washed with
 PBS and 0.5% bovine serum albumin (Sigma) and
tained with 5 L of anti-CD8 conjugated to strepta-
idin-phycoerythrin (CD8-PE; Pharmingen, San Di-
go, CA) for 20 minutes in the dark. The cells were
xed and permeabilized for 20 minutes by using the
ytoﬁx/Cytoperm Kit (Pharmingen) and stained with
L of anti–IFN- conjugated with streptavidin-
llophycocyanin (APC) for 30 minutes at 4°C in the
ark. Samples were washed twice with 1 Cytoﬁx
ash Solution (BD Biosciences, Pharmingen, San
ose, CA) and analyzed with the ﬂuorescence-acti-
ated cell sorter (FACS) FACSCalibur (Becton Dick-
nson, San Jose, CA). The lymphocytes were gated on
Table 1. Demographics of the 11 Allogeneic Stem Cell Transplant Subjects
Patient
No. Diagnosis
CMV Serostatus
(Donor/Recipient)
Hematopoietic
Stem Cell
Source HLA
CMV PCR
(Genome
Copies/mL)* CMV BC
Antiviral
Treatment
Grade of GVHD
(Months after
HCT)
Medication
>1 mg/kg/d Clinical Outcome
53 ALL Ph D/R Sibling PBSC A0101 A0201 neg neg No GVHD of the
mouth (1-8)
CSA: 0-6 mo MMF:
day 28 to 6 wk
Alive
65 CML D/R UD BM A0201 A1101 neg neg No None Alive
76 ALL D/R UD BM A0201 A6901 neg neg No GVHD II: skin
and gut (1);
liver (5); skin
and eyes (5)
PSE 3 d; FK506 0-3
mo; PSE 6-7;
MMF 6-9
Dead: multiorgan
failure (20 mo)
81 Pre–B-ALL D/R Sibling PBSC A0206 A2402 neg neg No GVHD: liver (4) CSA 4-5 mo; MMF
4-5 mo; PSE 4-12
mo
Alive
91 ALL D/R Sibling PBSC A0201 A2601 neg neg No GVHD II: gut (1);
liver (4)
CSA 0-1 mo Alive
98 CML D/R Sibling PBSC A0205 A1101 neg neg No GVHD: mouth
(1); liver (4)
PSE 15 d; CSA 15 d Alive
54 Biphenotypic
leukemia
D/R UD BM A0101 A0201 1416-10,234 (37) Yes (69) GCV CMV colitis;
GVHD III: gut
(1); mouth,
eyes (10)
PSE 3 d; MMF 1-4
mo
Alive
70 AML D/R Sibling PBSC A0203 A0206 4755-12,331 (41) Yes (41) GCV GVHD II: gut (1);
stomatitis (2)
CSA 0-15 mo; PSE
1-6 mo; MMF 8-
12 mo
Alive
93 ALL D/R Sibling PBSC A0201 A3001 202-1838 (39) Yes (55) GCV GVHD III: gut
and liver (2)
CSA 2-3 mo; MMF
2-3 mo; PSE 2-3
mo
Alive
94 Hodgkin
disease
D/R UD PBSC A0201 A0301 neg Yes (50) GCV GVHD: gut and
liver (2)
CSA 2-3 mo; MMF
2-3 mo
Alive
105 CML D/R Sibling PBSC A0201 A6803 205 (72) neg No None Alive
ALL indicates acute lymphoblastic leukemia; CML, chronic myelocytic leukemia; AML, acute myelogenous leukemia; UD, unrelated donor; PBSC, peripheral blood stem cells; BM, bone marrow; GCV,
ganciclovir; BC, blood culture; GVHD, graft-versus-host disease; CSA, cyclosporine; PSE, prednisone; MMF, mycophenolate mofetil; FK506, tacrolimus; Ph, philadelphia chromosome positive;
neg, the result was negative for CMV infection.
*Number of days after HCT to ﬁrst positivity are shown in parentheses.
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8he basis of forward and side scatter, and a minimum
f 50 000 events were analyzed per sample. The re-
orted data are the values obtained after subtraction of
ackground levels observed with HIV peptide stimu-
ation (range, 0%-0.5%). On the basis of analysis of
MV-negative donors, a limit of detection of 1  105
ells per liter was established.
LA-A*0201 Tetramer Binding
The HLA-A*0201 tetramers were prepared as de-
cribed previously [8] by using the individual CMV
eptides to fold the HLA-A*0201 heavy chain and
2-microglobulin, which were then biotinylated and
onjugated with streptavidin-APC (Pharmingen). The
amples from each patient were thawed at 37°C,
ashed with 1 PBS with 0.5% bovine serum albu-
in, and transferred into polystyrene round-bot-
omed FACS tubes (Becton Dickinson). Aliquots were
hen individually labeled with 0.5 to 1 g of tetpp65-
95, tetIE1-297, and tetIE1-316 and incubated for
hour on ice in the dark. The samples were washed
nd stained with 5 L of anti-CD8 conjugated to
treptavidin-phycoerythrin, incubated for 20 min-
tes, washed again, and, ﬁnally, analyzed by FACS. A
uropean multicenter evaluation of this method has
een established and validated as a reproducible rou-
ine diagnostic assay for the enumeration of antigen-
peciﬁc CD8 T cells [28].
tatistical Analyses
Data were analyzed with GraphPad Prism soft-
are (GraphPad Software, Inc., San Diego, CA). The
ann-Whitney U test was used to derive P values for
omparing data between groups.
ESULTS
linical Course of CMV Infection for 1 Year
fter HCT
Among the initial 11 recipients studied (Table 1)
o establish whether we could readily detect reconsti-
ution of cellular immunity to CMV IE-1, 5 subjects
patients 54, 78, 93, 94, and 105) had at least 1 CMV-
ositive blood sample by shell vial or had a qualifying
MV DNA quantitative PCR–positive assay in blood
lasma. In addition, subject 54 had disease diagnosed
s CMV colitis by biopsy. CMV positivity in blood
as determined in 4 of 5 subjects for each assay. Of
ote, patient 54’s donor and the donor for patient 93
ere CMV seronegative: this may have explained the
rolonged CMV infection detected in these recipi-
nts. Six of these subjects had no detectable CMV
nfection (no-CMV group).
GVHD grade II or less occurred in 2 subject in the
MV group and in 6 subjects in the no-CMV group,
nd GVHD grade greater than II occurred in 2 sub- 1
94ects in the CMV group and in 0 subjects in the
o-CMV group. Thus, as anticipated, GVHD was
ore severe in the CMV group, and the exposure to
rednisone therapy at a dose of 1 mg/kg/d was
reater in this group (Table 1). Ganciclovir was used
nly in the CMV group, but there was a clinical
ecision not to treat patient 105, who was CMV pos-
tive by quantitative PCR only. The overall survival
5/6 versus 5/5) and disease relapse (none) rates for
hese subjects at 1 year after HCT were the same, and
VHD grade III and CMV reactivation were the
ain clinical parameters that differentiated the 2
roups.
requency of IFN- Response to CMV Peptide
timulation in the Pilot CMV Group and
o-CMV Group
To evaluate the immune reactivity to CMV in
LA-A*0201 subjects, cryopreserved PBLs were
timulated with peptides derived from CMV pp65 and
MV IE-1 proteins. To ensure the functionality of
he stimulated cells, only the samples that responded
o phytohemagglutinin stimulation were reported.
uring the year of observation, the percentage of
pecimens obtained from subjects in the 2 groups was
he same (80% and 77.7%), and all specimens were
nalyzed for reactivity to pp65-495, IE-1-256, IE-1-
97, and IE-1-316 peptide stimulation. Figure 1 de-
cribes the overall frequency of IFN-–positive T-cell
pecimens in the 2 groups. The CMV group had a
igher overall frequency of positive specimens reac-
ive to pp65-495, IE-1-256, IE-1-297, and IE-1-316
eptide stimulation. It was noted that the immune
econstitution to CMV after HCT was characterized
y recognition directed to multiple IE-1 peptides in
ll subjects of the CMV group but that the response to
E-1 peptides in the no-CMV group was generally
egative or low.
inetics of ICC/IFN-–Positive Cells after HCT in
he CMV Group and No-CMV Group
To better understand the occurrence of immune
eactivity to these antigens, blood samples were
ollected at days 40, 90, 120, 150, 180, and 360 after
CT, and the results were expressed as the total
umber of IFN-–reactive cells  105 per liter
Figure 2). The IFN-–positive cells in the CMV
roup stimulated with pp65-495 peptide (Figure
A) peaked at day 120 and 150 after HCT, reaching
edian levels of 2.75  107 cells per liter, and
eptide-responsive cells were still present at 1 year
day 360 median, 3.12  107 cells per liter). The
evels of pp65-495–speciﬁc IFN-–positive cells in
he no-CMV group reached a peak (median, 1.8 
06 cells per liter) at day 150 and decreased to 3.0 
05 cells per liter after 1 year (Figure 2C). With the
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CMV ICC and Tetramer Binding
Bonparametric Mann-Whitney 2-tailed test, there
as no signiﬁcant difference by using the mean ICC
evel of each subject and the highest peak reached
etween those with and without CMV infection
compare Figure 2A and C; P  .08).
The IFN-–positive cells stimulated with IE-1-
56, IE-1-297, and IE-1-316 were reported as the
um of the total number of cells  105/L for the
valuation of the response to CMV IE-1, as shown
n Figure 2B and D. As indicated by the difference
n the y-axis range, the levels of CMV IE-1/IFN-
–positive responsive cells were a log lower than the
MV pp65–speciﬁc levels and did not seem to in-
rease until late after HCT. The median CMV IE-1
mmune response in the CMV group was 3.8  106
ells per liter at 1 year (Figure 2B) compared with 4
105 cells per liter in the no-CMV group (Figure
D). The level of ICC response to CMV pp65 as
ompared with IE-1 peptides was signiﬁcantly dif-
erent (Mann-Whitney test; P  .03) in the CMV
eactivation group, but there was no such difference
n the no-CMV group. In summary, a detectable
umber of T cells were reactive to CMV pp65 and
E-1 in the CMV group, but because the sampling
as small, there was no signiﬁcant difference be-
ween the CMV infection group and the no-CMV
roup. For this reason, a larger cohort of subjects
as analyzed (see below).
elationship between CMV Reactivation by PCR
nd Levels of CMV-Reactive Cells by ICC in the
MV Reactivation Group
The question of what effect CMV reactivation
as on CMV immune reconstitution was addressed
igure 1. ICC/IFN-–positive samples expressed as a percentage of
ll samples tested in patients with CMV reactivation or without
MV reactivation (no-CMV group). After overnight stimulation
ith individual CMV peptides (pp65-495, IE-1-256, IE-1-297, and
E-1-316), samples were analyzed for IFN- by using an intracel-
ular cytokine (ICC) assay as described in “Patients and Methods.”
he detection limit was 0.01% of CD8/IFN-–positive cells or 1
105 cells per liter after subtraction of background data by using an
IV peptide.y comparing the timing to the 2 events. CMV 4
B&MTeactivation started at a median of 55 days after
CT, and, as shown in Figure 3, the immune re-
ponses after this infection varied for individual
ecipients, with no predictable expansion of T cells
eactive to any speciﬁc CMV peptide or peptides of
p65 or IE-1. To summarize the observations in
his group of subjects, the presence of an ICC re-
ponse to pp65-495 did not automatically imply
eactivity to CMV IE-1 peptides (Figure 3; subjects
4 and 105), nor did the absence of a brisk response
o CMV pp65 mean that there would not be a
obust CMV IE-1 response (Figure 3; subjects 70
nd 94). Despite the administration of immunosup-
ressive drugs, there was evidence of a high level of
p65-495–reactive CD8 cells in the presence of
rolonged CMV infection (Figure 3; subject 93).
he prolonged CMV infection was also found in
ubject 54, and the low levels of CD8 responses to
p65 or IE-1 corresponded to heightened immuno-
uppression with prednisone and mycophenolate
ofetil (Table 1). Of note, there was a simultaneous
esponse to all 3 IE-1 peptides within the same
ample in all subjects at some time after CMV
nfection, but this was never observed in the no-
MV group (data not shown).
ssessment of the Immune Response by
etramer-Binding Assay
HLA-A*0201 tetramers labeled with the APC
olecule were prepared with pp65-495, IE-1-297,
nd IE-1-316 peptides, and the binding of these
etramers was evaluated on the same samples tested
or IFN- ICC (Figure 4). The CMV reactivation
roup was deﬁned by high levels of CD8/tetpp65-
95 cells that appeared at day 120 after HCT (me-
ian, 6.36  107 cells per liter) and was maintained
hroughout the year (day 360 median, 8.23  107
ells per liter; Figure 4A). In contrast, the number
f cells binding to CD8/tetIE-1-297 and CD8/
etIE-1-316, expressed as a sum, steadily increased
o a median of 3.7  106 cells per liter at day 360
Figure 4B). Of note, the median levels of CD8/
etpp65-495 and CD8/tetIE-1 at day 40 after
CT in the CMV reactivation group were similar
median, 5  106 and 7.4  106 cells per liter,
espectively). However, upon CMV reactivation,
he immune cells speciﬁc for CMV pp65 increased
o 7.58  107 cells per liter by day 150, whereas the
ells speciﬁc to CMV IE-1 decreased to 1.8  106
ells per liter. Of note, the no-CMV group devel-
ped a peak median CD8/tetpp65-495 cell count
t a later time (median, 2.28  107 cells per liter at
ay 180; this decreased to 4  105 cells per liter by
year; Figure 4C). Although higher at day 40 in the
MV reactivation group, the levels of CD8/
etIE-1 remained the same in both groups (Figure
B and 4D) throughout subsequent observation in
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8he year after transplantation. The tetramer-bind-
ng data therefore indicate that the CMV-speciﬁc
D8 immune cells are present in reasonably high
uantity in HCT subjects during hematopoietic re-
onstitution whether or not there is detectable
MV reactivation.
urther Evaluation of pp65 and IE-1 Peptide Pools
n HLA-A*0201 Subjects
On the basis of this experience indicating that
CC-positive cells could be observed after stimula-
ion with individual IE-1 peptides, the follow-up
rotocol used fresh whole blood cells from HCT
ubjects stimulated with an IE-1 mixture of these
eptides speciﬁc for HLA-A*0201: namely, CMV
E-1-256, IE-1-297, and IE-1-316 and the pp65-
95 peptide. Figure 5 shows the results of 23 sub-
ects with CMV reactivation (Figure 5A and C) and
igure 2. Levels of CMV-speciﬁc CD8/IFN-–positive cells at va
n the CMV-reactivation group (A and B) and in the no-CMV grou
ells stimulated with IE-1-256, IE-1-297, and IE-1-316. The numb
hown after subtraction of background data by using HIV peptide sti
n the graph as a continuous line.f 10 subjects (Figures 5B and D) in the no-CMV t
96roup followed up for 1 year. IFN- responsiveness
o CMV pp65 peptide (Figures 5A and B) and to
E-1 (Figure 5C and D) was compared between
roups. With use of a contingency table (Fisher
xact test) to test whether CMV reactivation was
redictive for the presence of either CMV pp65–
eactive or CMV IE-1–reactive cells at any time
fter transplantation, there were no signiﬁcant dif-
erences between groups. The CMV group dis-
layed more CMV pp65–reactive T cells (compare
igure 5A and B) and CMV IE-1–reactive T cells
compare Figure 5C and D), but these levels were
ot signiﬁcantly different.
ime to First Evidence of CD8 IFN-–Positive
MV-Specific T Cells after HCT
We next asked whether there was a difference in
es after HCT. CMV peptide–speciﬁc CD8 cells were stimulated
nd D). A and C, Cells stimulated with pp65-495. B and D, Sum of
FN-–positive cells, expressed as x times 1  105 cells per liter, is
n. The median value was calculated at each time point and is shownrious tim
p (C a
er of I
mulatiohe time to ﬁrst demonstration of immune reconsti-
t
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Bution in the CMV and no-CMV groups. For this, we
eﬁned immune reconstitution as the ﬁrst observation
f at least 1  105/L CD8 IFN- responsive to pp65-
95 peptide (Figure 6A) or to IE-1 peptide mixture
Figure 6B). There was no difference between subjects
ith and without CMV infection in the time to ﬁrst
igure 3. CMV immunity and CMV infection. CMV reactivation i
t the top of the graph showing the time to PCR positivity after H
A), and IE-1–speciﬁc peptides consisting of IE-1-256, IE-1-297, an
ells, expressed as x times 1  105 cells per liter (y-axis), is shown af
ime after HCT for each subject is on the x-axis, and, when availabl
olony-stimulating factor treatment (PreG and PostG, respectivelyvidence of T-cell immunity by either pp65 or IE-1 m
B&MTesponses. An important observation is that the time
o immune reconstitution was at least as early and
omplete in subjects with no detectable CMV infec-
ion as in the subjects in whom CMV reactivation was
een. One hundred percent immune reconstitution
as never attained in the subjects who had docu-
for each individual (patients 54, 70, 93, 94, and 105) as a bold line
he number of pp65-495–speciﬁc /IFN-–positive cells is shown in
-316 stimulation are shown in (B). The number of IFN-–positive
raction of background data by using HIV peptide stimulation. The
umber of cells is shown for the donor before and after granulocytes shown
CT. T
d IE-1
ter subt
e, the nented CMV infection. In all recipients, however, if
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8mmune reconstitution was to occur during the ﬁrst
ear after HCT, then it was present by 6 months.
ISCUSSION
In this work, the evaluation of CMV immunity in
CT HLA-A*0201 subjects relied on 2 assays (the
CC/IFN- and tetramer-binding assays) and on re-
ctivity to 2 major CMV proteins (CMV pp65 and
MV IE-1). This is the ﬁrst comparative study that
sed both of these antigens to characterize the time of
MV immune reconstitution after HCT. The tet-
amer-binding assay has been widely used because it
ermits the quantiﬁcation of cytotoxic T lymphocytes
n a simple assay by using ﬂow cytometry [8,11,
3,14,18,29-39]. It is useful for measuring cellular
igure 4. Time course of tetramer-positive T cells after HCT. The
um of tetramer-positive cells speciﬁc to IE-1-297 and IE-1-316 (B
ith documented CMV reactivation, and the right panels (C and D
umber of IFN-–positive cells is shown as x times 1  105 cells p
n the graph as a continuous line.mmune responses to CMV pp65 because it targets 4
98ainly 1 immunodominant epitope, the pp65-495 of
he HLA-A*0201 allele. Other epitopes encompassing
MV pp65 have been described for other HLA al-
eles, thus suggesting that CMV pp65 is a major target
or immune responses [5]. In contrast, the CMV IE-1
rotein presents multiple peptides in the same HLA
ontext and therefore requires multiple tetramer re-
gents. This places added requirements on the tet-
amer technology for determining the immune status
f an individual, but multiplex tetramer reagents have
een developed to address this. Our report shows that
he median value of CD8/tet cells binding to
etpp65-495 in subjects with documented CMV infec-
ion after HCT, expressed as the concentration of
ells per microliter, was 10-fold higher than that in
atients with no such CMV infection. Also, the pp65-
er of tetramer-positive cells speciﬁc to pp65-495 (A and C) and the
are shown. The left panels (A and B) represent results for subjects
sent results in subjects with no documented CMV infection. The
, and the median value is calculated at each time point and shownnumb
and D)
) repre
er liter95 peptide–speciﬁc response was consistently higher
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Bhan the IE-1–speciﬁc response. Of note, when com-
ared with the ICC assay at peak time, only 43% of
p65-495-tet cells were expressing IFN- (compare
igure 2A and Figure 4A); this suggests that more
han half of the tet cells were not functional and
grees with the results of others [1,32,37].
During CMV reactivation, the CMV IE-1 protein
s the ﬁrst protein to be expressed in infected cells,
igure 5. Levels of CMV-speciﬁc CD8/IFN-–positive cells at var
ubjects stimulated with CMV-pp65 peptide (A and B) or a mixtur
hown. A and C, Number of cells obtained in recipients with detect
etectable CMV infection (10 subjects).
igure 6. Percentage of HCT recipients with CMV-speciﬁc T-cell
timulated with pp65 (A) or a mixture of IE-1 peptides (B) is show
nfection (CMV group) are shown as a continuous line, and those w
he log-rank test showed no signiﬁcant differences between the 2 curves
B&MTnd, therefore, it should be part of the immune re-
ponse during immune reconstitution. By using the
eptides uncovered with the HLA-A*0201 transgenic
ouse model, namely, the CMV IE-1-256, -297, and
316 peptides [23], PBLs from HCT recipients were
timulated and tested by ICC/IFN- assay at various
imes up to 1 year after HCT. After detectable CMV
eactivation, all 3 CMV IE-1 peptides stimulated
es after HCT. An ICC assay on fresh blood from 33 HLA-A*0201
-1–speciﬁc peptides (CMV IE-1-256, -297, and -316; C and D) is
V reactivation (23 subjects). B and D, Results from those with no
e reconstitution. The cumulative incidence of IFN-–positive cells
indicated times after HCT. The recipients with detectable CMV
detectable CMV infection (no CMV) are shown as a hatched line.ious tim
e of IE
able CMimmun
n at the
ith noin (A) and (B).
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9BLs in all 5 subjects at some time between day 40
nd day 360 after HCT. There was no indication that
ne peptide use was more prominent than the others
n the CMV reactivation group; therefore, a CMV
E-1 peptide mixture was used in the follow-up study
f 33 subjects to determine the detection of immune
ellular reactivity. Moreover, in the HLA-A*0201
ontext, the immune response in the CMV reactiva-
ion group to CMV IE-1 was always lower than that to
MV pp65. The highest median value was observed
t day 360 (Figure 2B), thus suggesting that there may
e additional antigenic stimulation and expansion af-
er CMV reactivation. The CMV IE-1 ICC cell count
as still low at day 180 even though the median time
o the ﬁrst day of CMV reactivation was day 55 after
CT.
The pp65 response increased briskly between days
00 and 180 after HCT and remained high at 1 year,
specially after CMV infection. In the no-CMV
roup, there was a low-level tet response to both
p65-495 and IE-1 during the same period, and this
opulation of T cells never expanded, remaining at
ery low levels at 1 year. It is likely that exposure to
MV antigen is required for these CD8 expansions
nd that, in the no-CMV group, if there was an initial
MV reactivation state, it was then limited, never
eached detectable levels in blood, and was never
ufﬁcient to lead to expansion of CD8-speciﬁc cells.
evertheless, on the basis of these immunologic
bservations, it seems that many allogeneic HCT
ecipients at risk for CMV undergo occult CMV
eactivation even when there is no documented infec-
ion. The fact that the patients with no detectable
MV infection had the earlier and the most complete
mmune reconstitution to CMV suggests a previously
nrecognized phenomenon of subclinical CMV reac-
ivation that is shown only by the occurrence of
MV-reactive T cells.
The question is why there is a reduced response to
MV IE-1 compared with pp65. The immune system
ay not be exposed as much to the IE protein during
he reactivation process as it would be during a pri-
ary infection. Indeed, in congenital and postnatal
MV infection, IE-1–speciﬁc responses dominated by
year of age, regardless of the speciﬁcity of initial
esponses [22]. This response to the CMV IE-1 gene
s a typical response to a primary infection and is in
ontrast to what is seen in adults with chronic infec-
ion. In HLA-A*0201 HCT subjects, although the
esponse to CMV pp65 always predominates, the re-
ponse to CMV IE-1 was detectable and present in the
MV group. It is noteworthy that 3 subjects in the
MV reactivation group showed ICC positivity to all
CMV IE-1 peptides simultaneously at day 360, but
his was never seen in the no-CMV group. These
esults show for the ﬁrst time a multipeptidic IE-1–
peciﬁc immune response within the same blood sam-
00les. By tetramer-binding assay, we know that CD8
ells are directed toward IE-1-297 and IE-1-316 in
qual numbers in both the CMV reactivation and
o-CMV groups, and when they are shown combined
n Figure 4B and D, there is still no signiﬁcant differ-
nce between groups. Therefore, although the num-
er of CMV IE-1 immune cells is small, they are
resent in sufﬁcient number and seem to respond to
ocumented or occult CMV reactivation. It remains
o be determined whether this response contributes to
rotection from progressive infection.
The CMV-speciﬁc T-cell immunity observed in
he recipients with no CMV infection could have been
assively transferred in the graft, and this would ac-
ount for the increased numbers of T cells at day 40.
n this relatively small study, the percentage of recip-
ents with 1  105 IFN- CD8 cells at this early
ime after HCT was not signiﬁcantly different. How-
ver, of note, the number of immune subjects in the
o-CMV group continued to increase despite the ab-
ence of detectable CMV infection. This suggests that
he transfer of CMV-reactive T cells might protect
rom detectable CMV infection, perhaps by control of
irus replication after reactivation, and this justiﬁes
ttempts to augment the transfer of such cells at the
ime of HCT to test such a hypothesis. The manipu-
ation of donor cells either by in vitro expansion or by
n vivo stimulation with a vaccine may prevent CMV
eactivation through such adoptive immune therapy.
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